We conducted a randomized , double-blind , active-controlled , phase 3 study involving 1841 patients with relapsing-remitting multiple sclerosis to compare daclizumab HYP , administered subcutaneously at a dose of 150 mg every 4 weeks , with interferon beta-1a , administered intramuscularly at a dose of 30 g once weekly , for up to 144 weeks .